^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Liquid Trace™ Solid Tumor

Type:
Laboratory Developed Test
Related tests:
Evidence

News

12ms
Sysmex Inostics and Genomic Testing Cooperative form partnership to accelerate therapeutic discovery and development (Genomic Testing Cooperative Press Release)
"Sysmex Inostics Inc...and Genomic Testing Cooperative (GTC), based in Irvine, California, formed a strategic partnership for Sysmex Inostics to commercialize GTC’s tissue and liquid biopsy solid tumors and hematology assay services to biopharma customers. This includes GTC’s Solid Tumor Profile Plus, Liquid Trace Solid Tumor Profile, Liquid Trace Hematology Profile, and Hematology Profile Plus assay services."
Licensing / partnership
|
Hematology Profile Plus • Liquid Trace™ Hematology • Liquid Trace™ Solid Tumor • Solid Tumor Profile Plus
over1year
Genomic Testing Cooperative to present data at the American Society of Hematology meeting on new applications of its proprietary tests that combine transcriptome data obtained from tissue or liquid biopsies with machine learning (Genomic Testing Cooperative Press Release)
"Genomic Testing Cooperative, LCA (GTC) announced the presentation of four innovative studies at the annual American Society of Hematology (ASH) meeting that will be held from December 10 to 13, 2022 in New Orleans, Louisiana...GTC continues to demonstrate the superior capabilities of their new cell-free (cfDNA) and cell-free RNA (cfRNA) liquid biopsy test called Liquid Trace."
Clinical data
|
Liquid Trace™ Hematology • Liquid Trace™ Solid Tumor
almost2years
Genomic Testing Cooperative to reveal “Liquid Trace™” at ASCO, a liquid biopsy test that combines cell-free dna with targeted transcriptome and to present data on its advanced AI for the diagnosis of hematologic and solid tumors (Genomic Testing Cooperative Press Release)
"Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the American Society of Clinical Oncology (ASCO) 2022 annual meeting data showcasing its new innovative approach to liquid biopsy testing that combines both cell-free-DNA (cfDNA) with cell-free RNA (cfRNA), Liquid Trace™. Liquid Trace tests both cfDNA and cfRNA not only improves sensitivity of the liquid biopsy but also provides transcriptome data that is enriched by various tumor markers (CA125, CA 15-3, CEA, etc) and makes it possible to perform liquid immunoprofiling by evaluating levels of CD19, CD20, CD33, CD4, CD8, etc."
Clinical data
|
Liquid Trace™ Hematology • Liquid Trace™ Solid Tumor